Educational information, reviewed by Ryan Arvizo, FNP-C. Current as of November 2026.
On October 30, 2026, a federal notice titled Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances was published in the Federal Register (Federal Register 2026-22192). Some headlines read it as “peptides are legal now.” The text is much narrower than that, and the difference matters if you are deciding whether to start, or keep taking, one of these therapies.
What the policy says, in one paragraph
The Department of Health and Human Services (HHS) says it does not intend to take enforcement action against state-licensed pharmacies and licensed prescribers that compound six specific peptides from bulk ingredients, but only in the forms and routes the policy lists, and only when every one of its conditions is met (Baker Hostetler summary). The full list of the six is in the notice itself.
Three things it is not
It is not FDA approval. None of the six becomes an FDA-approved drug. The policy does not add them to the official list of substances pharmacies may compound under section 503A. A law firm that reviewed it put it plainly: the policy “does not create a safe harbor” (Hall Render).
It is not final. The notice was published as an interim policy with a comment period that closed on November 13, 2026 (docket HHS-OASH-2026-0496). It lasts only until FDA finishes rulemaking on the compounding list, and HHS says it may revise or withdraw it if safety or quality problems appear (Federal Register 2026-22192).
It is not unopposed. Before the policy published, a patient-safety group filed a citizen petition asking FDA not to allow compounding of these peptides by any route (Partnership for Safe Medicines). During the comment period, a policy group asked HHS to withdraw it (American Action Forum). The policy’s own appendix shows that FDA’s drug center recommended against listing these peptides, and HHS sided with its advisory committee instead (Hall Render).
The conditions are the point
The policy only applies when the supply chain meets specific conditions. Among them (Baker Hostetler; ArentFox Schiff):
- A real prescription for one patient. Not office stock and not a standing supply.
- A known original manufacturer, registered with FDA, for the bulk ingredient, with its name and address on the certificate of analysis. A distributor’s name is not enough.
- Only the listed forms and routes. Some of the six are covered only as a topical or nasal product, not as an injection.
- Single ingredient. The policy does not cover blends of several substances in one product.
- Required labeling and adverse-event reporting.
Most of these conditions sit with the pharmacy. That is why the most useful question a patient can ask is not “is this legal now?” but “does the pharmacy filling my prescription meet these conditions, and can you show me?”
What it does not cover at all
Products sold online “for research use only,” supplements, and anything from a source that is not a state-licensed pharmacy filling an individual prescription are outside the policy (Hall Render). If a website points to this policy to sell you a vial without a provider evaluation, it is using the headline, not the text.
What happens next
HHS can finalize the policy, revise it, or withdraw it, and it can be challenged in court. FDA’s advisory committee is also scheduled to review a second group of peptides before the end of February 2027 (FDA Pharmacy Compounding Advisory Committee). Any of those steps can change what is available. Plans built on “approved by Christmas” were early before the policy published, and they still are.
How BioPeakRx handles it
Nothing at BioPeakRx is sold to a cart. A licensed provider evaluates you first, decides whether any therapy is appropriate, and anything prescribed is prepared by a state-licensed U.S. pharmacy for you alone. When federal policy changes, your provider will tell you what it means for your plan, including when the honest answer is “not yet.”
Sources
- Federal Register, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (2026-22192, October 30, 2026; docket HHS-OASH-2026-0496)
- Baker Hostetler, HHS issues enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances
- Hall Render, HHS, not FDA, takes the lead on peptide compounding (November 4, 2026)
- ArentFox Schiff, Compound interest: HHS’s new peptide policy, the China supply chain and Blue Wave
- Partnership for Safe Medicines, petition press release (October 21, 2026)
- American Action Forum, Comments to HHS regarding peptide compounding
- FDA, Pharmacy Compounding Advisory Committee meeting page
This information is educational and is not medical or legal advice. It is not intended to diagnose, treat, cure, or prevent any disease. Compounded medications are not FDA-approved. Treatments require evaluation by a licensed provider.
